Galmed Pharmaceuticals’ (GLMD) “Hold” Rating Reiterated at Maxim Group

Galmed Pharmaceuticals (NASDAQ:GLMD)‘s stock had its “hold” rating restated by stock analysts at Maxim Group in a note issued to investors on Friday,Benzinga reports.

Separately, StockNews.com started coverage on shares of Galmed Pharmaceuticals in a report on Friday, March 28th. They set a “sell” rating for the company.

Galmed Pharmaceuticals Trading Down 8.2 %

Shares of Galmed Pharmaceuticals stock opened at $1.34 on Friday. The firm’s 50 day moving average is $2.22 and its 200 day moving average is $3.20. The firm has a market capitalization of $862,960.00, a PE ratio of -0.08 and a beta of 0.70. Galmed Pharmaceuticals has a 1 year low of $1.28 and a 1 year high of $23.80.

Institutional Trading of Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC acquired a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned 3.97% of Galmed Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 76.14% of the company’s stock.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.